Acamprosate and naltrexone: similar efficacy for relapse
Saitz, R.
Revue Medicale Suisse 10(455): 2437
2014
ISSN/ISBN: 1660-9379 PMID: 25752019 Document Number: 677064
Document emailed within 1 workday
Related Documents
Hoque, M.Monjurul.; Hossain, K.Jahangir.; Kamal, M.Mustafa.; Akhtaruzzaman, M. 2009: Naltrexone in drug addiction: significance in the prevention of relapse Mymensingh Medical Journal: Mmj 18(1 Suppl): S56-S65Cibin, M.; Gentile, N.; Ferri, M.; Gallimberti, L. 1989: Naltrexone and prevention of opiate dependence relapse. An Italian experience Minerva Psichiatrica 30(2): 93-98
Krupitskiĭ, E.M. 2014: Injectable extended-release naltrexone for the prevention of relapse to opioid dependence following opioid detoxification Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 114(5 Pt 2): 64-72
Malspeis, L.; Bathala, M.S.; Ludden, T.M.; Bhat, H.B.; Frank, S.G.; Sokoloski, T.D.; Morrison, B.E.; Reuning, R.H. 1975: Metabolic reduction of naltrexone. I. Synthesis, separation and characterization of naloxone and naltrexone reduction products and qualitative assay of urine and bile following administration of naltrexone, alpha-naltrexol, or beta-naltrexol Research Communications in Chemical Pathology and Pharmacology 12(1): 43-65
Faro, G.; Jarre, P.; Martucci, M.; Sargiotto, A.; Eandi, M. 1991: Use of naltrexone in the treatment of opiate addicts. Efficacy and indications for type categories La Clinica Terapeutica 139(3-4): 93-99
Rouillon, F.; Serrurier, D.; Miller, H.D.; Gerard, M.J. 1991: Prophylactic efficacy of maprotiline on unipolar depression relapse Journal of Clinical Psychiatry 52(10): 423-431
McKenzie, J. 2000: Information needs of patients with cancer. Similar study had similar findings Bmj 321(7261): 632; Author Reply 633
Dienstbier, Z.; Hermanská, Z.; Zámecník, J.; Melínová, L.; Vacková, B.; Skala, E.; Srbová, D. 1995: Relapse in Hodgkin's disease. Incidence of relapse in a group of 374 patients from 1 June 1968 to 31 March 1995 Vnitrni Lekarstvi 41(12): 816-821
Schmid, H.; von Schenck, U.; Hartmann, R.; Borgmann, A.; Henze, G. 1996: Allogeneic BMT vs. chemotherapy in late bone marrow relapsed childhood non-T/non-B ALL: results of BFM ALL relapse studies. BFM Relapse Study Group Bone Marrow Transplantation 18(Suppl 2): 28-30
Jantz, M.A. 2001: Acute exacerbation of idiopathic pulmonary fibrosis and fibroproliferative acute respiratory distress syndrome: similar disease, similar treatment? Respiratory Care 46(7): 664-665
Suvanchot, K.Sinsak.; Somrongthong, R.; Phukhao, D. 2012: Efficacy of group motivational interviewing plus brief cognitive behavior therapy for relapse in amphetamine users with co-occurring psychological problems at Southern Psychiatric Hospital in Thailand Journal of the Medical Association of Thailand 95(8): 1075-1080
Yamada, K.; Kawasumi, Y.; Yasuda, A.; Seki, Y.; Adachi, T.; Tarumi, O.; Hayashi, Y.; Nakagawa, T.; Yamada, N.; Ogawa, K. 2016: Changes in Mac Antibody Levels before and after Surgery and at the time of Relapse/Recurrence in Mac Lung Disease--Can Mac Antibodies be an Indicator of Postoperative Relapse/Recurrence? Kekkaku: 91(2): 41-44
2014: Safety and efficacy of brentuximab vedotin (SGN-35) in Hodgkin lymphoma patients undergoing reduced intensity allogeneic stem cell transplant following a relapse after autologous transplant Clinical Advances in Hematology and Oncology: H&o 12(8 Suppl. 16): 20
Pace, N.L.; Parrish, R.G.; Lieberman, M.M.; Wong, K.C.; Blatnick, R.A. 1979: Pharmacokinetics of naloxone and naltrexone in the dog Journal of Pharmacology and Experimental Therapeutics 208(2): 254-256
Jaros, J.; Lio, P. 2019: Low Dose Naltrexone in Dermatology Journal of Drugs in Dermatology: Jdd 18(3): 235-238
Porat, S.; Shufman, E.N.; Witztum, E. 1993: Prevention of heroin reabuse--value of naltrexone Harefuah 125(3-4): 115-119
Kmoch, V.; Papezova, H.; Yamamotova, A. 2009: Two patients with eating disorders treated by naltrexone Neuro Endocrinology Letters 30(3): 327-330
Malcolm, R.; O'Neil, P.M.; Sexauer, J.D.; Riddle, F.E.; Currey, H.S.; Counts, C. 1985: A controlled trial of naltrexone in obese humans International Journal of Obesity 9(5): 347-353
Chuong, C.J.; Coulam, C.B.; Bergstralh, E.J.; O'Fallon, W.M.; Steinmetz, G.I. 1988: Clinical trial of naltrexone in premenstrual syndrome Obstetrics and Gynecology 72(3 Pt 1): 332-336
Misra, A.L.; Bloch, R.; Vardy, J.; Mulé, S.J.; Verebely, K. 1976: Disposition of (15,16-3H)naltrexone in the central nervous system of the rat Drug Metabolism and Disposition: the Biological Fate of Chemicals 4(3): 276-280